Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients

Ramon A Gil; Nelson Hwynn; Thomas Fabian; Sovi Joseph; Hubert H Fernandez

doi:10.1016/j.parkreldis.2011.01.007

Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients

Parkinsonism Relat Disord. 2011 May;17(4):285-7. doi: 10.1016/j.parkreldis.2011.01.007. Epub 2011 Feb 5.

Authors

Ramon A Gil¹, Nelson Hwynn, Thomas Fabian, Sovi Joseph, Hubert H Fernandez

Affiliation

¹ Parkinson's Disease Treatment Center of SW Florida (d/b/a Charlotte Neurological Services), 4235 Kings Highway, Port Charlotte, FL 33980, USA. gilramon@hotmail.com

PMID: 21296606
DOI: 10.1016/j.parkreldis.2011.01.007

Abstract

Gastroparesis is a very common non-motor feature in Parkinson's disease (PD) patients. However, treatment options are limited and difficult. We present 2 cases of PD patients with excellent response to botulinum toxin type A as treatment for PD-related gastroparesis.

Publication types

Case Reports

MeSH terms

Aged
Botulinum Toxins, Type A / therapeutic use*
Female
Gastric Emptying / drug effects
Gastroparesis / drug therapy*
Gastroparesis / etiology
Humans
Male
Neuromuscular Agents / therapeutic use*
Parkinson Disease / complications*

Substances

Neuromuscular Agents
Botulinum Toxins, Type A